July 2009 Volume 6 Number 7
Visit Nature Reviews Urology online to browse the journal.
Now available at http://links.ealert.nature.com/ctt?kn=23&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access
to Nature Reviews Urology online. To purchase a subscription, please visit:
http://links.ealert.nature.com/ctt?kn=14&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=26&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
*********************************************************************
Nature Reviews Urology Impact Factor: 2.104*
(*Journal Citation Reports, Thomson, 2005)
*********************************************************************
=========================== ADVERTISEMENT ===========================
Nature Reviews Urology brings all the qualities of the top-ranked life
sciences series to the clinical sciences and is a valuable resource for
practicing physicians and clinical academics.
Visit Nature Reviews Urology online at
http://links.ealert.nature.com/ctt?kn=85&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
and keep up-to-date with the latest advances in urology.
=====================================================================
----------------------
RESEARCH HIGHLIGHTS
----------------------
BPH: Black box warning for tamsulosin?
p345 | doi:10.1038/nrurol.2009.116
http://links.ealert.nature.com/ctt?kn=78&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
Prostate Cancer: Tumor cells driven to suicide by inactivated virus
p346 | doi:10.1038/nrurol.2009.114
http://links.ealert.nature.com/ctt?kn=83&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
IN BRIEF
Prostate cancer | Prostate cancer | Prostate cancer | Pathology
p346 | doi:10.1038/nrurol.2009.121
http://links.ealert.nature.com/ctt?kn=20&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
Risk factors: Glutathione S-transferase polymorphism and prostate cancer
p347 | doi:10.1038/nrurol.2009.112
http://links.ealert.nature.com/ctt?kn=3&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
Prostate cancer: Molecular markers and prognosis
p347 | doi:10.1038/nrurol.2009.120
http://links.ealert.nature.com/ctt?kn=53&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
Speak plainly about prostate cancer
p347 | doi:10.1038/nrurol.2009.71
http://links.ealert.nature.com/ctt?kn=71&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
TURP OK for BPH in Parkinson disease
p348 | doi:10.1038/nrurol.2009.115
http://links.ealert.nature.com/ctt?kn=34&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
Urinary incontinence: Behavioral intervention enhances pharmacological
therapy
p348 | doi:10.1038/nrurol.2009.117
http://links.ealert.nature.com/ctt?kn=8&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
Surgery: Laparoscopic versus open nephroureterectomy
p349 | doi:10.1038/nrurol.2009.118
http://links.ealert.nature.com/ctt?kn=4&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
IN BRIEF
Surgery | Male factor infertility | Male factor infertility | Pediatrics
p349 | doi:10.1038/nrurol.2009.122
http://links.ealert.nature.com/ctt?kn=92&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
Prostate Cancer: Type of biopsy probe determines detection rate
p350 | doi:10.1038/nrurol.2009.113
http://links.ealert.nature.com/ctt?kn=82&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
Prostate cancer: New endothelin-A receptor antagonist prolongs survival
p350 | doi:10.1038/nrurol.2009.119
http://links.ealert.nature.com/ctt?kn=17&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
Correction: Integrative medicine: complementary therapies and supplements
p350 | doi:10.1038/nrurol.2009.128
http://links.ealert.nature.com/ctt?kn=69&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Urinary Incontinence: Oxybutynin topical gel for overactive bladder
Christopher R. Chapple
p351 | doi:10.1038/nrurol.2009.111
Antimuscarinic drugs are the first-line treatment for overactive bladder.
However, traditional formulations are associated with a number of adverse
effects, most notably dry mouth. A study comparing a new topical gel
formulation of oxybutynin to placebo has confirmed its efficacy and
tolerability for treating overactive bladder.
http://links.ealert.nature.com/ctt?kn=48&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
Surgery: Centers of excellence for penile prosthesis: yes or no?
Tariq F. Al-Shaiji and Gerald B. Brock
p352 | doi:10.1038/nrurol.2009.109
Emerging data indicate that outcomes of surgical procedures are improved
if surgery is performed in high-volume hospitals or by high-volume surgeons.
This principle seems to hold true for penile prosthesis surgery, but careful
consideration is necessary before adopting a 'center of excellence' model
for this, or any, procedure.
http://links.ealert.nature.com/ctt?kn=27&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
Clinical trials: Nationally representative data in urology
Jay B. Shah and Vitaly Margulis
p354 | doi:10.1038/nrurol.2009.104
Retrospective analyses of single-institution experiences are difficult
to generalize to the population as a whole. The emerging trend of utilizing
national datasets and disease registries provides information relatable
to the average patient that may prove considerably more useful to community
urologists.
http://links.ealert.nature.com/ctt?kn=41&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
Risk factors: Improved risk stratification for prostate cancer
Hendrik Isbarn and Pierre I. Karakiewicz
p355 | doi:10.1038/nrurol.2009.106
An algorithm used to evaluate risk in patients with prostate cancer has
been improved by taking into account the quantity of risk factors present.
The adapted scheme accurately predicts disease-specific mortality, and
reveals that prostate cancer is the major cause of death in patients with
three or more risk factors.
http://links.ealert.nature.com/ctt?kn=35&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
Genetics: Susceptibility loci in a molecular subtype of prostate cancer
Robert J. Klein
p357 | doi:10.1038/nrurol.2009.108
Genetic linkage has recently been reported between several genomic loci
and a subtype of prostate cancer that contains a fusion between the genes
TMPRSS2 and ERG. These data suggest an analytical approach that might
improve future studies of the genetic cause of prostate and other cancers.
http://links.ealert.nature.com/ctt?kn=56&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
Clinical guidelines: Should 5[alpha]-reductase inhibitors be used for
prostate disease?
Noel W. Clarke
p358 | doi:10.1038/nrurol.2009.105
A new guideline from the US has neatly summarized the evidence regarding
the use of 5[alpha]-reductase inhibitors for prostate disease, but falls
short of providing definitive management recommendations. It will, however,
be a valuable aid to both patients and physicians in the clinical
decision-making process.
http://links.ealert.nature.com/ctt?kn=75&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
Pain: Easing the pain: local anesthesia for prostate biopsy
Katsuto Shinohara
p360 | doi:10.1038/nrurol.2009.110
The importance of prostate biopsy is undisputed, but the procedure can
be excruciatingly painful for some men. Does combined anesthesia aimed
at addressing the two sources of pain associated with transrectal
ultrasound-guided prostate biopsy provide a more effective form of pain
relief than either modality alone?
http://links.ealert.nature.com/ctt?kn=25&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
Surgery: Laparoscopic prostatectomy: learning curve and cancer control
Steven L. Chang and Mark L. Gonzalgo
p361 | doi:10.1038/nrurol.2009.107
Greater surgeon experience is associated with lower recurrence rates
following laparoscopic radical prostatectomy for prostate cancer. A new
study shows that the learning curve for this procedure is slower than that
for open surgery, and highlights the challenges of developing the unique
skills that are required to master each technique.
http://links.ealert.nature.com/ctt?kn=89&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
----------------------
REVIEWS
----------------------
Contemporary imaging of incidentally discovered adrenal masses
Milton D. Gross, Melvyn Korobkin, Wessam Bou Assaly, Ben Dwamena and
Mehdi Djekidel
Published online: 09 June 2009
p363 | doi:10.1038/nrurol.2009.100
Modern, high-resolution imaging modalities frequently reveal adrenal masses
in patients being assessed for other reasons. Once discovered, algorithms
that employ CT, MRI and PET-as well as modifications of these techniques-are
used to narrow the very broad differential diagnosis. Here, Milton Gross
and colleagues summarize what the urologist needs to know about the imaging
features of etiologically distinct adrenal masses.
Abstract: http://links.ealert.nature.com/ctt?kn=77&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=46&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy
E. Jason Abel and Christopher G. Wood
Published online: 16 June 2009
p375 | doi:10.1038/nrurol.2009.102
The development of targeted therapy for renal cell carcinoma (RCC) has
changed the treatment options for patients with metastatic RCC. The authors
of this Review discuss the current and future role of cytoreductive
nephrectomy in combination with targeted therapies, and the rationale for
presurgical therapy for this group of patients.
Abstract: http://links.ealert.nature.com/ctt?kn=6&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=68&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
Prostate kallikrein markers in diagnosis, risk stratification and prognosis
David Ulmert, M. Frank O'Brien, Anders S. Bjartell and Hans Lilja
p384 | doi:10.1038/nrurol.2009.123
The discoverer of free PSA and his colleagues assess the clinical utility
of this most widely used disease biomarker. The article encompasses recently
published data from randomized screening trials, and the potential of PSA
density, dynamics and subforms to enhance the predictive capacity of total
PSA. The PSA characteristics of BPH, prostatitis and prostate cancer are
summarized, and the effects of age and obesity presented.
Abstract: http://links.ealert.nature.com/ctt?kn=86&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=95&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
----------------------
CASE STUDY
----------------------
A G-CSF-secreting adrenal carcinoma with rhabdoid-like differentiation
causing leukocytosis
Emil Lou et al.
p392 | doi:10.1038/nrurol.2009.101
The authors describe a 57-year-old man with paraneoplastic leukocytosis,
caused by overexpression of granulocyte-colony stimulating factor from
a suprarenal tumor with rhabdoid-like differentiation. This case presented
several diagnostic and treatment challenges to the pathologists, surgeons,
and oncologists involved, and illustrates the difficulties encountered
when diagnosing and treating unusual malignancies.
Abstract: http://links.ealert.nature.com/ctt?kn=59&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=72&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
----------------------
PERSPECTIVES
----------------------
OPINION
A management algorithm for hematospermia
Muhammad I. Aslam, Philippa Cheetham and Marek A. W. Miller
p398 | doi:10.1038/nrurol.2009.98
The causes of blood in the ejaculate are usually benign, and the condition
self-limiting. Nevertheless, many patients are worried by such a dramatic
symptom. This concern, together with the small risk of malignancy, drives
clinical investigation. UK-based authors have reviewed the literature in
an effort to provide a clear and concise strategy for the evaluation of
men with hematospermia.
Abstract: http://links.ealert.nature.com/ctt?kn=70&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=42&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Visit the Nature Reviews Urology website:
- Advanced online publication
- Search across related content from nature.com
- Web feeds (RSS)
- Downloadable PowerPoint slides of figures and supplementary information
http://links.ealert.nature.com/ctt?kn=85&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted
in to receive it. You can change or discontinue your e-mail alerts at
any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=10&m=33524446&r=MTc2NDg0NjM5NAS2&b=2&j=NTI2NDM4MjES1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
